- Home
- NEA vs SNY Comparison
NEA vs SNY Comparison
Compare NEA & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEA
- SNY
- Stock Information
- Founded
- NEA 2002
- SNY 1994
- Country
- NEA United States
- SNY France
- Employees
- NEA N/A
- SNY N/A
- Industry
- NEA Finance/Investors Services
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- NEA Finance
- SNY Health Care
- Exchange
- NEA Nasdaq
- SNY Nasdaq
- Market Cap
- NEA N/A
- SNY 116.5B
- IPO Year
- NEA N/A
- SNY N/A
- Fundamental
- Price
- NEA $11.01
- SNY $48.70
- Analyst Decision
- NEA
- SNY Buy
- Analyst Count
- NEA 0
- SNY 2
- Target Price
- NEA N/A
- SNY $62.50
- AVG Volume (30 Days)
- NEA 803.4K
- SNY 2.1M
- Earning Date
- NEA 01-01-0001
- SNY 07-24-2025
- Dividend Yield
- NEA 4.23%
- SNY 3.31%
- EPS Growth
- NEA N/A
- SNY 39.56
- EPS
- NEA N/A
- SNY 5.45
- Revenue
- NEA N/A
- SNY $48,817,552,946.00
- Revenue This Year
- NEA N/A
- SNY $3.39
- Revenue Next Year
- NEA N/A
- SNY $7.05
- P/E Ratio
- NEA N/A
- SNY $17.56
- Revenue Growth
- NEA N/A
- SNY N/A
- 52 Week Low
- NEA $9.20
- SNY $45.80
- 52 Week High
- NEA $11.37
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- NEA 63.56
- SNY 43.32
- Support Level
- NEA $10.79
- SNY $47.64
- Resistance Level
- NEA $10.97
- SNY $49.37
- Average True Range (ATR)
- NEA 0.06
- SNY 0.68
- MACD
- NEA 0.02
- SNY 0.14
- Stochastic Oscillator
- NEA 93.18
- SNY 30.56
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.